A Single-Center, Randomized, Double-blind, Placebo-controlled, Single and Multiple Dosing, Dose-escalation, Phase 1 Clinical Trial to Evaluate the Safety, Tolerability, PK/PD, Food Effect of HW201877 in Healthy Volunteers
Latest Information Update: 04 Feb 2026
At a glance
- Drugs HW 201877 (Primary)
- Indications Inflammatory bowel diseases
- Focus Adverse reactions
- Sponsors Wuhan Humanwell Innovative Drug Research and Development Center
Most Recent Events
- 04 Feb 2026 New trial record